Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 31-September 1, 2020, the OWC Pharmaceutical Research Corp. (the
"Company") held a special meeting of stockholders (the "Meeting") for
stockholders to vote on the following proposals: (i) to authorize the Company's
Board of Directors to effect one reverse stock split of the Company's
outstanding Common Stock, $0.00001 par value per share, at any ratio between
1-for-10 and 1-for-20 at such time as the Company's Board of Directors shall
determine, in its sole discretion, before September 7, 2020 ("Proposal No. 1");
(ii) to amend the Company's Certificate of Incorporation, as amended to increase
the number of the Company's authorized shares of Common Stock from 500,000,000
shares to 2,500,000,000 shares ("Proposal No. 2"); and (iii) to approve one or
more adjournments to the Meeting, if necessary or appropriate, to permit further
solicitation of proxies if there are not sufficient votes at the time of the
Meeting cast in favor of Proposals No. 1 and/or No. 2 ("Proposal No. 3").
As of August 4, 2020, (the "Record Date") for the Meeting, there were
497,498,338 shares of the Company's Common Stock issued and outstanding and
entitled to vote with one vote per share on each proposal, 381 shares of the
Company's Series A Preferred Stock, which entitled the holders thereof to an
aggregate of 24,825,167 votes and 43,675 shares of the Company's Series B
Preferred Stock issued and outstanding and were entitled to an aggregate of
43,675,000 votes.
In order to conduct the business of the Meeting, the Company required the
presence, in person or by proxy, of a quorum consisting of a majority of the
outstanding shares of stock entitled to vote as of the Record Date. A quorum was
not present at the Meeting, no business was conducted, and pursuant to the
Company's bylaws, the Company's stockholders approved an adjournment of the
Meeting to September 14, 2020 (the "Adjournment Date"), to allow additional time
for stockholders to vote, obtain a quorum and seek approval for Proposals No. 1
and 2.
The vote results for Proposal 3, the only proposal that had an effect due to the
absence of a quorum at the Meeting were as follows:
Votes For Votes Against Abstentions
98,147,681 97,874,905 21,439,195
The Company will amend this Current Report on Form 8-K to report the results of
the vote on Proposals 1 and 2 following the Adjournment Date.
© Edgar Online, source Glimpses
OWC PHARMACEUTICAL RESEARCH CORP. 
